3,4-Methylenedioxy-N-propylamphetamine

MDPR
Clinical data
Other names3,4-Methylenedioxy-N-propylamphetamine; MDPR; N-Propyl-MDA
Routes of
administration		Oral
Drug classPsychoactive drug
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown
Identifiers
  • N-[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.217.125 Edit this at Wikidata
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
  • CC(NCCC)Cc1ccc2OCOc2c1
  • InChI=1S/C13H19NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h4-5,8,10,14H,3,6-7,9H2,1-2H3
  • Key:LBXMQBTXOLBCCA-UHFFFAOYSA-N
  (verify)

MDPR, also known as 3,4-methylenedioxy-N-propylamphetamine or as N-propyl-MDA, is a lesser-known psychoactive drug and a substituted amphetamine.

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDPR's minimum dose as 200 mg orally and its duration as unknown. MDPR is described as a "promoter"; by itself it has almost no effects on the mind, but it promotes the effects of hallucinogens, similarly to the closely related MDPH. Shulgin reported that 160 mg of MDPR strongly enhanced the effects of a small (60 μg) dose of LSD, and that similar enhancement of hallucinogenic effect was noted when mixing MDPR with other drugs such as psilocybin, mescaline, 2C-B, and 2C-T-7. The reason for this synergistic action of MDPR has not been elucidated.

Chemistry

Synthesis

The chemical synthesis of MDPR has been described.

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. MDPR entry
  2. 1 2 Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.